Ying Jura, MD
Urology · Stanford, CANPI 1407983869
Payments from drug & device makers
Across 27 payments — averaging $28.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$214
- Coloplast$177
- Cook Medical LLC$70
- Olympus America Inc.$59
- Urogen Pharma, Inc.$56
- C. R. Bard, Inc. & Subsidiaries$46
- plus $135 from 6 others
What the payments were for
- Food & beverage$756100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $214 |
| Coloplast | 6 | $177 |
| Cook Medical LLC | 2 | $70 |
| Olympus America Inc. | 2 | $59 |
| Urogen Pharma, Inc. | 2 | $56 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $46 |
| Siemens Medical Solutions USA, Inc. | 1 | $28 |
| KARL Storz Endoscopy-america | 1 | $26 |
| Laborie Medical Technologies Corp. | 1 | $26 |
| Medtronic | 1 | $21 |
| Fujifilm Healthcare Americas Corporation | 1 | $19 |
| Ambu Inc. | 1 | $16 |
How this compares
$756 in reported general payments places this provider in the 30th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 233 | $264,974 |
| Mirabegron ErMirabegron | 78 | $40,938 |
| Tamsulosin Hcl | 210 | $4,078 |
| Estradiol | 67 | $3,026 |
| Finasteride | 122 | $1,863 |
| Trospium Chloride | 25 | $1,216 |
| Terazosin Hcl | 21 | $946 |
| Cephalexin | 83 | $804 |
| Solifenacin Succinate | 29 | $677 |
| Cefpodoxime Proxetil | 13 | $376 |
| Ciprofloxacin Hcl | 41 | $297 |
| Ibuprofen | 26 | $258 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $163 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $134 |
| Tramadol Hcl | 16 | $100 |
Paid to pharmacies, not to this prescriber.
Other urology in Stanford
- Bogdana SchmidtStanford$362K
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.